Denna sida på svenska
Loading profile information...


Detailed gene dose analysis reveals recurrent focal gene deletions in pediatric B-cell precursor acute lymphoblastic leukemia
Ivanov Öfverholm I, Tran An, Olsson L, Zachariadis V, Heyman M, Rudd E, et al
Leukemia & lymphoma 2016;57(9):2161-70

Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy
Thielen N, Richter J, Baldauf M, Barbany G, Fioretos T, Giles F, et al
Clinical cancer research : an official journal of the American Association for Cancer Research 2016;22(16):4030-8

PAX5-ESRRB is a recurrent fusion gene in B-cell precursor pediatric acute lymphoblastic leukemia
Marincevic-zuniga Y, Zachariadis V, Cavelier L, Castor A, Barbany G, Forestier E, et al
Haematologica 2016;101(1):e20-3

A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR
White H, Deprez L, Corbisier P, Hall V, Lin F, Mazoua S, et al
Leukemia 2015;29(2):369-76

DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia
Nordlund J, Bäcklin Cl, Zachariadis V, Cavelier L, Dahlberg J, Öfverholm I, et al
Clinical epigenetics 2015;7():11-

Increased p53 protein expression as a potential predictor of early relapse after hematopoietic stem cell transplantation in children with acute myelogenous leukemia
Mattsson K, Honkaniemi E, Barbany G, Gustafsson B
Pediatric transplantation 2015;19(7):767-75

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia
Cross Nc, White He, Colomer D, Ehrencrona H, Foroni L, Gottardi E, et al
Leukemia 2015;29(5):999-1003

The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013
Olsson L, Ivanov Öfverholm I, Norén-nyström U, Zachariadis V, Nordlund J, Sjögren H, et al
British journal of haematology 2015;170(6):847-58

The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia
Paulsson K, Lilljebjörn H, Biloglav A, Olsson L, Rissler M, Castor A, et al
Nature genetics 2015;47(6):672-6

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia
Zabriskie Ms, Eide Ca, Tantravahi Sk, Vellore Na, Estrada J, Nicolini Fe, et al
Cancer cell 2014;26(3):428-442

Clinical and genetic features of pediatric acute lymphoblastic leukemia in Down syndrome in the Nordic countries
Lundin C, Forestier E, Klarskov Andersen M, Autio K, Barbany G, Cavelier L, et al
Journal of hematology & oncology 2014;7():32-

Detecting dic(9;20)(p13.2;p11.2)-positive B-cell precursor acute lymphoblastic leukemia in a clinical setting using fluorescence in situ hybridization
Zachariadis V, Schoumans J, Ofverholm I, Barbany G, Halvardsson E, Forestier E, et al
Leukemia 2014;28(1):196-8

Elevated p53 protein expression; a predictor of relapse in rare chronic myeloid malignancies in children?
Honkaniemi E, Mattsson K, Barbany G, Sander B, Gustafsson B
Pediatric hematology and oncology 2014;31(4):327-39

High modal number and triple trisomies are highly correlated favorable factors in childhood B-cell precursor high hyperdiploid acute lymphoblastic leukemia treated according to the NOPHO ALL 1992/2000 protocols
Paulsson K, Forestier E, Andersen Mk, Autio K, Barbany G, Borgström G, et al
Haematologica 2013;98(9):1424-32

Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols
Ofverholm I, Tran An, Heyman M, Zachariadis V, Nordenskjöld M, Nordgren A, et al
Leukemia 2013;27(9):1936-9

Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients
Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-dahl T, et al
Leukemia 2013;27(7):1520-6

Loss of chromosomes is the primary event in near-haploid and low-hypodiploid acute lymphoblastic leukemia
Safavi S, Forestier E, Golovleva I, Barbany G, Nord Kh, Moorman Av, et al
Leukemia 2013;27(1):248-50

The ETV6/RUNX1 fusion transcript is not detected in RNA isolated from neonatal dried blood spots from children later diagnosed with the corresponding leukemia
Barbany G, Gauffin F, Öfverholm I, Karlsson H, Thörn I, Arvidson J, et al
Leukemia & lymphoma 2013;54(12):2742-4

Additional aberrations of the ETV6 and RUNX1 genes have no prognostic impact in 229 t(12;21)(p13;q22)-positive B-cell precursor acute lymphoblastic leukaemias treated according to the NOPHO-ALL-2000 protocol
Barbany G, Andersen Mk, Autio K, Borgström G, Franco Lc, Golovleva I, et al
Leukemia research 2012;36(7):936-8

Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers
Consortium Investigators Modifiers, Kconfab Investigators, Gemo Study Collaborators, Embrace, Hebon, Swe-brca, et al

Donor cell-derived acute myeloid leukemia after second allogenic cord blood transplantation in a patient with Fanconi anemia
Gustafsson B, Moell J, Leblanc K, Barbany G, Söderhäll S, Winiarski J
Pediatric transplantation 2012;16(6):E241-5

Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome
Ohm L, Arvidsson I, Barbany G, Hast R, Stenke L
American journal of hematology 2012;87(8):760-5

Homozygous deletions of CDKN2A are present in all dic(9;20)(p13·2;q11·2)-positive B-cell precursor acute lymphoblastic leukaemias and may be important for leukaemic transformation
Zachariadis V, Schoumans J, Barbany G, Heyman M, Forestier E, Johansson B, et al
British journal of haematology 2012;159(4):488-91

The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation
Eurochimerism Consortium, Lion T, Watzinger F, Preuner S, Kreyenberg H, Tilanus M, et al
LEUKEMIA 2012;26(8):1821-8

Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2
Cimba, Kconfab, Swe-brca, Embrace, Hebon, Osorio A, et al
BRITISH JOURNAL OF CANCER 2011;104(8):1356-61

Exploring the link between MORF4L1 and risk of breast cancer
Gemo Study Collaborators, Swe-brca, Bcfr, Hebon, Kconfab, Embrace, et al

Paediatric B-cell precursor acute lymphoblastic leukaemia with t(1;19)(q23;p13): clinical and cytogenetic characteristics of 47 cases from the Nordic countries treated according to NOPHO protocols
Andersen Mk, Autio K, Barbany G, Borgstrom G, Cavelier L, Golovleva I, et al

The frequency and prognostic impact of dic(9;20)(p13.2;q11.2) in childhood B-cell precursor acute lymphoblastic leukemia: results from the NOPHO ALL-2000 trial
Nordic Soc Pediat Hematology Oncol, Sclsg, Zachariadis V, Gauffin F, Kuchinskaya E, Heyman M, et al
LEUKEMIA 2011;25(4):622-8

Applicability of IG/TCR gene rearrangements as targets for minimal residual disease assessment in a population-based cohort of Swedish childhood acute lymphoblastic leukaemia diagnosed 2002-2006
Thorn I, Forestier E, Thuresson B, Wasslavik C, Malec M, Li Ah, et al

Molecular monitoring and mutation analysis of patients with advanced phase CML and Ph plus ALL receiving dasatinib
Olsson-stromberg U, Hermansson M, Lundan T, Ohm Ac, Engdahl I, Hoglund M, et al

Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers
Cimba, Breast Canc Family Registry, Gemo, Embrace, Hebon, Ocgn, et al
HUMAN MOLECULAR GENETICS 2009;18(22):4442-56

Monitoring minimal residual disease with flow cytometry, antigen-receptor gene rearrangements and fusion transcript quantification in Philadelphia-positive childhood acute lymphoblastic leukemia
Thorn I, Botling J, Hermansson M, Lonnerholm G, Sundstrom C, Rosenquist R, et al
LEUKEMIA RESEARCH 2009;33(8):1047-54

Quantitation of RNA decay in dried blood spots during 20 years of storage
Gauffin F, Nordgren A, Barbany G, Gustafsson B, Karlsson H

Characterization of 6q deletions in mature B cell lymphomas and childhood acute lymphoblastic leukemia
Thelander Ef, Ichimura K, Corcoran M, Barbany G, Nordgren A, Heyman M, et al
LEUKEMIA & LYMPHOMA 2008;49(3):477-87

Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic myeloid leukemia
Gupta M, Milani L, Hermansson M, Simonsson B, Markevarn B, Syvdnen Ac, et al

Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements
Saldanha J, Silvy M, Beaufils N, Arlinghaus R, Barbany G, Branford S, et al
LEUKEMIA 2007;21(7):1481-7

Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma
Thelander Ef, Ichimura K, Collins Vp, Walsh Sh, Barbany G, Hagberg A, et al
LEUKEMIA RESEARCH 2007;31(9):1219-30

Gene expression analysis identifies a genetic signature potentially associated with response to alpha-IFN in chronic phase CML patients
Hagberg A, Olsson-stromberg U, Wickenberg-bolin U, Goransson H, Isaksson A, Bengtsson M, et al
LEUKEMIA RESEARCH 2007;31(7):931-8

Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis
Olsson-stromberg U, Aleskog A, Bjornberg A, Hoglund M, Simonsson B, Bengtsson M, et al
ANTI-CANCER DRUGS 2006;17(6):631-9

In vitro activity of imatinib in cells from patients with adult acute lymphoblastic leukemia
Hallbook H, Barbany G, Aleskog A, Bjornberg A, Larsson R, Sundstrom C, et al
ANTI-CANCER DRUGS 2005;16(6):631-4

The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia
Thorn I, Olsson-stromberg U, Ohsen C, Jonsson Am, Klangby U, Sinnonsson B, et al

Vascular endothelial growth factor gene expression in middle cerebral artery occlusion in the rat
Lennmyr F, Terent A, Syvanen Ac, Barbany G

Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease - a study within the Europe Against Cancer Program
Europe Against Canc Program, Van Der Velden Vhj, Boeckx N, Gonzalez M, Malec M, Barbany G, et al
LEUKEMIA 2004;18(4):884-6

Beta-globin mRNA increases rapidly during erythropoietin treatment
Hagberg A, Barbany G, Landegren U, Birgegard G

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - A Europe Against Cancer Program
Gabert J, Beillard E, Van Der Velden Vhj, Bi W, Grimwade D, Pallisgaard N, et al
LEUKEMIA 2003;17(12):2318-57

Complete molecular remission in chronic myelogenous leukemia after imatinib therapy
Swedish Cml Grp, Barbany G, Hoglund M, Simonsson B

RNA-templated DNA ligation for transcript analysis
Nilsson M, Antson Do, Barbany G, Landegren U
NUCLEIC ACIDS RESEARCH 2001;29(2):578-81

Enhanced detection and distinction of RNA by enzymatic probe ligation
Nilsson M, Barbany G, Antson Do, Gertow K, Landegren U

Expression profiling across many samples via manifold-assisted mRNA processing
Hagberg A, Barbany G, Krook H, Samiotaki M, Landegren U
Nucleic acids research 2000;28(11):E54-

Manifold-assisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients
Barbany G, Hagberg A, Olsson-stromberg U, Simonsson B, Syvanen Ac, Landegren U
CLINICAL CHEMISTRY 2000;46(7):913-20

Molecular genetic applications of streptavidin-coated manifold supports
Barbany G, Hagberg A, Waldenstrom E, Landegren U

Show all publications